Advanced Search
LI Zhijun, ZHANG Jie, ZHANG Li, TONG Zhongsheng. Clinicopathologic Characteristics and Prognosis of De Novo Metastatic Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2019, 46(11): 998-1005. DOI: 10.3971/j.issn.1000-8578.2019.19.0543
Citation: LI Zhijun, ZHANG Jie, ZHANG Li, TONG Zhongsheng. Clinicopathologic Characteristics and Prognosis of De Novo Metastatic Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2019, 46(11): 998-1005. DOI: 10.3971/j.issn.1000-8578.2019.19.0543

Clinicopathologic Characteristics and Prognosis of De Novo Metastatic Breast Cancer Patients

More Information
  • Corresponding author:

    TONG Zhongsheng, E-mail:tongzhongsheng@tjmuch.com

  • Received Date: April 27, 2019
  • Revised Date: August 11, 2019
  • Available Online: January 12, 2024
  • Objective 

    To analyze the clinicopathological characteristics and prognosis of de novo metastatic breast cancer(DnMBC) patients, so as to provide some guidance for clinical diagnosis and treatment.

    Methods 

    We retrospectively analyzed the clinicopathologic characteristics of 124 DnMBC patients treated in the Tianjin Medical University Cancer Hospital from January 2011 to December 2016. Univariate and multivariate analysis were carried out for the survival and prognosis. Subgroup analysis was performed to analyze the effect of surgical treatment on the prognosis of patients.

    Results 

    The median age at diagnosis of 124 patients was 53(26-77) years old. The median follow-up time was 29 months, the median progression-free survival PFS) and overall survival(OS) were 14(10.6-17.4) and 35(29.1-40.9) months, respectively. ER status and primary tumor stage were independent influence factors of PFS and OS(P < 0.05).

    Conclusion 

    The clinicopathological characteristics of DnMBC patients are more invasive, with a higher risk of progression. Palliative surgical treatment may improve the prognosis of HR+/HER2- patients with large primary tumor. Therefore, individualized treatment as needed is particularly important.

  • [1]
    Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
    [2]
    Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial[J]. Lancet Oncol, 2015, 16(13): 1380-1388.
    [3]
    Cardoso F, Spence D, Mertz S, et al. Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015)[J]. Breast, 2018, 39: 131-138.
    [4]
    Malmgren JA, Mayer M, Atwood MK, et al. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010[J]. Breast Cancer Res Treat, 2018, 167(2): 579-590.
    [5]
    Yamamura J, Kamigaki S, Fujita J, et al. The Difference in Prognostic Outcomes Between De Novo Stage Ⅳ and Recurrent Metastatic Patients with Hormone Receptor-positive, HER2-negative Breast Cancer[J]. In Vivo, 2018, 32(2): 353-358.
    [6]
    Bhoo-Pathy N, Verkooijen HM, Tan EY, et al. Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian setting[J]. Sci Rep, 2015, 5: 16252.
    [7]
    Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period[J]. J Clin Oncol, 2004, 22(16): 3302-3308.
    [8]
    Leone BA, Vallejo CT, Romero AO, et al. Prognostic impact of metastatic pattern in stage Ⅳ breast cancer at initial diagnosis[J]. Breast Cancer Res Treat, 2017, 161(3): 537-548.
    [9]
    Cortesi L, Toss A, Cirilli C, et al. Twenty-years experience with de novo metastatic breast cancer[J]. Int J Cancer, 2015, 137(6): 1417-1426.
    [10]
    Lobbezoo DJ, van Kampen RJ, Voogd AC, et al. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?[J]. Br J Cancer, 2015, 112(9): 1445-1451.
    [11]
    Lee ES, Jung SY, Kim JY, et al. Identifying the potential long-term survivors among breast cancer patients with distant metastasis[J]. Ann Oncol, 2016, 27(5): 828-833.
    [12]
    den Brok WD, Speers CH, Gondara L, et al. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed[J]. Breast Cancer Res Treat, 2017, 161(3): 549-556.
    [13]
    Vaz-Luis I, Lin NU, Keating NL, et al. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype[J]. Breast Cancer Res Treat, 2015, 151(3): 697-707.
    [14]
    Soran A, Ozmen V, Ozbas S, et al. A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage Ⅳ breast cancer: Turkish Study (Protocol MF07-01)[C]. J Clin Oncol, 2016, 34.
    [15]
    Thomas A, Khan SA, Chrischilles EA, et al. Initial Surgery and Survival in Stage Ⅳ Breast Cancer in the United States, 1988-2011[J]. JAMA Surg, 2016, 151(5): 424-431.
    [16]
    Lambertini M, Ferreira AR, Di Meglio A, et al. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage Ⅳ or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study[J]. Clin Breast Cancer, 2017, 17(8): 601-610. e2.
    [17]
    Xiao W, Zou Y, Zheng S, et al. Primary tumor resection in stage IV breast cancer: A systematic review and meta-analysis[J]. Eur J Surg Oncol, 2018, 44(10): 1504-1512.
    [18]
    Badwe R, Parmar V, Hawaldar R, et al. Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: A randomized controlled trial[C]. Cancer Res, 2013, 73(24).
    [19]
    King TA, Lyman J, Gonen M, et al. A prospective analysis of surgery and survival in stage Ⅳ breast cancer (TBCRC 013)[C]. J Clin Oncol, 2016, 34.
    [20]
    Tripathy D, Kaufman PA, Brufsky AM, et al. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER[J]. Oncologist, 2013, 18(5): 501-510.
    [21]
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11): 783-792.
    [22]
    Molnár IA, Molnár Bá, Vízkeleti L, et al. Breast carcinoma subtypes show different patterns of metastatic behavior[J]. Virchows Arch, 2017, 470(3): 275-283.
    [23]
    Rossi V, Nolè F, Redana S, et al. Clinical outcome in women with HER2-positive de novo or recurring stage Ⅳ breast cancer receiving trastuzumab-based therapy[J]. Breast, 2014, 23(1): 44-49.
    [24]
    Wang H, Zhang C, Zhang J, et al. The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based study[J]. Oncotarget, 2017, 8(16): 26368-26379.
    [25]
    Tao L, Chu L, Wang LI, et al. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population[J]. Cancer Causes Control, 2016, 27(9): 1127-1138.
    [26]
    Savci-Heijink CD, Halfwerk H, Hooijer GK, et al. Retrospective analysis of metastatic behaviour of breast cancer subtypes[J]. Breast Cancer Res Treat, 2015, 150(3): 547-557.
    [27]
    Saraf A, Grubb CS, Hwang ME, et al. Breast cancer subtype and stage are prognostic of time from breast cancer diagnosis to brain metastasis development[J]. J Neurooncol, 2017, 134(2): 453-463.
  • Related Articles

    [1]SHAO Shengli, WANG Jiheng, LIU Shanting. Application and Thinking of Deep Learning in Predicting Lateral Cervical Lymph Node Metastasis of Papillary Thyroid Cancer[J]. Cancer Research on Prevention and Treatment, 2025, 52(1): 36-41. DOI: 10.3971/j.issn.1000-8578.2025.24.0761
    [2]ZHUANG Jinman, LU Wanting, HUANG Yuxiu, HU Zhijian, LIN Zheng, HE Fei. Risk Factors of Lymph Node Metastasis in Early-stage Cervical Cancer Patients and Build of A Nomogram Prediction Model[J]. Cancer Research on Prevention and Treatment, 2019, 46(1): 50-54. DOI: 10.3971/j.issn.1000-8578.2019.18.0942
    [3]DUAN Yongheng, ZHOU Lingdan, GAO Jian, LIN Sheng, ZHANG Linghua, GU Xueying, ZENG Xuchun, HONG Wenxu, DUAN Shan, HUANG Zijian. Relationship of Expression Difference of miR-658 and miR-492 with Pelvic Lymph Node Metastasis from Squamous Carcinoma of Cervix[J]. Cancer Research on Prevention and Treatment, 2016, 43(8): 699-703. DOI: 10.3971/j.issn.1000-8578.2016.08.010
    [4]HOU Zhichao, WANG Weipeng, HUANG Jia, LIU Yali, LIU Jing, TANG Sa, YUAN Guo, HU Yanlong, CHEN Lisha, SHI Lili, WANG Lidong. Impact of Lymph Node Metastasis and Relevant Risk Factors on Survival of Patients with Esophageal Carcinoma from High- and low-incidence Areas[J]. Cancer Research on Prevention and Treatment, 2014, 41(03): 221-226. DOI: 10.3971/j.issn.1000-8578.2014.03.006
    [5]Zhu Jingfeng, Ren Zhengbing, Gu Haiyong, Ma Shaojun, Liu Chao, Chen Suocheng. Association of Variant Allele of DICER and Decreased Risk of Esophageal Cancer Lymph Node Metastasis[J]. Cancer Research on Prevention and Treatment, 2012, 39(07): 822-825. DOI: 10.3971/j.issn.1000-8578.2012.07.014
    [6]ZENG Jin-yan. A Meta Analysis of Relationship between COX-2 Expression and Lymph Node Metastasis in Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(05): 584-587. DOI: 10.3971/j.issn.1000-8578.2011.05.028
    [7]DON G Li, L I Weiping, YAN Wenjing, WU Suxiang. Relationship between Expression of VEGF2D and MLD and Lymph Node Metastasis in En2 dometrial Carcinoma[J]. Cancer Research on Prevention and Treatment, 2008, 35(12): 885-887. DOI: 10.3971/j.issn.1000-8578.1921
    [8]GAO Zhao-hua. Analysis of Clinicopathologic Characteristics and Prognosis of Colorectal Cancer without Lymph Node Metastasis[J]. Cancer Research on Prevention and Treatment, 2008, 35(04): 272-274. DOI: 10.3971/j.issn.1000-8578.2697
    [9]PENG Yi-liang, LIANG Hou-jie, LIU Li-mei, YANG Jing, DUANG Guang-jie. The Expression of Podoplanin/VEGF-C and Lymph Node Metastasis in Human Colon Carcinoma[J]. Cancer Research on Prevention and Treatment, 2006, 33(08): 581-582. DOI: 10.3971/j.issn.1000-8578.1828
    [10]PEI Feng, FENG Mao-hui, YANG Guo-Liang, et al. The Relationship Between the Expression of nm23-H1 and Lymph Node Metastasis in Colorectal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2000, 27(05): 385-386. DOI: 10.3971/j.issn.1000-8578.192

Catalog

    Article views (2407) PDF downloads (1198) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return